Filing Flows › Mangoceuticals (MGRX) › Q3 2025
Mangoceuticals (MGRX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Mangoceuticals (MGRX) reported revenue of $84K for the third quarter 2025 (Q3 2025), -37% from a year earlier and -50% from the quarter before.
Mangoceuticals, Q3 2025: revenue $84K (-37% year over year), net loss $7.6M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $84K | -50% | -37% |
| Operating profit | −$7.5M | — | — |
| Net earnings | −$7.6M | — | — |
| Operating cash flow | −$1.2M | — | — |
What changed
Revenue was $84K in Q3 2025, down 37% year over year and down 50% from the previous quarter.
Gross margin was 60.4%, down 1.6 points from a year earlier. Operating costs exceeded revenue by $7.5M, an operating margin of -8953.5%. Operating expenses grew 313% against a revenue fall of 37%. The fastest-growing cost line was Other operating costs (+574%). The quarter ended with a net loss of $7.6M, wider than the previous quarter's $5.4M loss. Minority interests bore $1K of it: to shareholders the quarter was a loss of $7.6M.
Operating cash flow was −$1.2M. Non-cash charges added back $0K of depreciation and $1.1M of share-based compensation. Working capital and other items added $5.3M.
Questions
What was Mangoceuticals' revenue in the third quarter 2025?
Mangoceuticals (MGRX) reported revenue of $84K for the third quarter 2025 (Q3 2025), -37% from a year earlier and -50% from the quarter before.
Source: Mangoceuticals 10-Q on SEC EDGAR.